Scientists reported: “Our results clearly demonstrate that NIDA cannabis samples are substantially genetically different from most commercially available drug-type strains and share a genetic affinity with hemp samples in several of the analyses.”
The …
Category: NIDA
Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses.
US Government Approves Increased Production of Marijuana for Clinical Research
Federal officials have approved plans for the University of Mississippi to grow 2,000 kilograms (4,409 pounds) of cannabis to provide to investigators for clinical trial research.
Study: Marijuana Provided For FDA-Approved Clinical Research Genetically Similar to Hemp
Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado.
Legislation Introduced To End The Federal Government’s Marijuana Production Monopoly
A bipartisan coalition of over two-dozen federal lawmakers, including House Judiciary Chairman Bob Goodlatte (R-VA) and Matt Gaetz (R-FL), are backing newly introduced legislation — The Medical Cannabis Research Act of 2018 — to facilitate federally-approved clinical trials involving cannabis. Passage of this act would end the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes by requiring the licensing of additional manufacturers.
NIDA Director Says Cannabidiol Is A “Safe Drug”
The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.”
NIDA Acknowledges Drawbacks to Monopoly on Marijuana Supply
Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]
One Barrier to Cannabis Research Removed, Others Remain
It bears repeating that ample scientific research already exists to contradict cannabis’ federal, schedule I status as a substance without medical utility, lacking acceptable safety, and possessing a high potential of abuse. More clinical research is welcome, but unfortunately science has never driven marijuana policy. If it did, the United States would already have a very different policy in place.
Arizona: Government Money Used To Oppose Marijuana Legalization
Yavapai County Prosecutor Using Government Money To Oppose Marijuana Legalization
Feds Seek To Increase Marijuana Production Quotas
DEA Administrator Michele Leonhart filed paperwork today announcing that the agency is seeking to increase its marijuana production quota for the year 2015 by nearly three-fold.